Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Shots:

• The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system)
• The focus of an agreement is to advance management techniques for diabetes with the combination of the two technologies CGM & connected insulin pen, enabling healthcare professionals to monitor glucose and insulin data
• In H1’17, Novo signed a collaboration with Glooko for its platform connected to insulin pens for uploading data by any means of communication-capable Android phone. Abbott’s FreeStyle Libre system uses sensors allowing the monitor glucose levels in real-time with an eight-hour glucose history & change in glucose level

Click here to read full press release/ article | Ref: Abbott | Image: Twitter